{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:19:46Z","timestamp":1783423186070,"version":"3.54.6"},"reference-count":112,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Huzhou Science and Technology Bureau Public Welfare Application Research Project","award":["2024GZB08"],"award-info":[{"award-number":["2024GZB08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Bruton's tyrosine kinase (BTK) inhibitors are important targeted drugs for treating chronic B-cell malignancies, and have played a key role in improving patient prognosis and treatment efficacy. However, despite the significant advantages of BTK inhibitors in anti-tumor therapy, the use of these drugs also promotes certain cardiovascular risks, including atrial fibrillation (AF), bleeding, hypertension, heart failure, and potential ventricular arrhythmias (VAs). The latest generation of BTK inhibitors has shown progress in reducing the incidence of these adverse events; however, cardiovascular adverse events (CVAEs) cannot be ignored and continue to pose challenges to patient safety. Therefore, determining how to optimize the clinical application of Bruton\u2019s tyrosine kinase inhibitor (BTKi) further has become an urgent problem. This review systematically analyzes the pathogenesis and clinical manifestations of BTK inhibitor-related cardiovascular complications, with a particular focus on the epidemiological characteristics and potential risk factors of common adverse reactions, such as hypertension, AF, bleeding, and stroke. Moreover, this review explores the pathological and physiological mechanisms, further evaluates the effectiveness of current risk management and intervention strategies, and proposes future research to elucidate mechanisms, optimize doses, and explore combination therapy. Meanwhile, through in-depth analysis and comprehensive evaluation of existing data, this review aims to provide a more scientific basis for clinical decision-making, while promoting research into the safety of continuous BTK inhibitor use to achieve improved treatment outcomes while balancing efficacy and safety.<\/jats:p>","DOI":"10.31083\/rcm47740","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:15Z","timestamp":1783422375000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9240-5698","authenticated-orcid":true,"given":"Haojian","family":"Gan","sequence":"first","affiliation":[{"name":"School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7465-8442","authenticated-orcid":true,"given":"Junling","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6353-1143","authenticated-orcid":true,"given":"Jiayi","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2314-0048","authenticated-orcid":true,"given":"Qingjian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6563-0037","authenticated-orcid":true,"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3951-2919","authenticated-orcid":true,"given":"Yu","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3057-0972","authenticated-orcid":true,"given":"Bicheng","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9600-9956","authenticated-orcid":true,"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers. 2021; 13: 1103.","DOI":"10.3390\/cancers13051103"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Shen J, Li J, Yang R, Wu S, Mu Z, Ding S, et al. Advances in the treatment of mantle cell lymphoma with BTK inhibitors. Leukemia Research. 2024; 147: 107615.","DOI":"10.1016\/j.leukres.2024.107615"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A, Pawlak D. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules (Basel, Switzerland). 2023; 28: 2400.","DOI":"10.3390\/molecules28052400"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Belo Nunes R, Baiocchi OC, Marques MO, Bachour P, Avezum A. Cardiovascular and non-cardiovascular adverse events in patients with hematologic malignacies treated with BTK inhibitors: a real-world analysis. European Heart Journal. 2024; 45: ehae666.3171.","DOI":"10.1093\/eurheartj\/ehae666.3171"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhao Y, Chakraborty P, Tomassetti J, Subha T, Mass\u00e9 S, Thavendiranathan P, et al. Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. International Journal of Molecular Sciences. 2024; 25: 6207.","DOI":"10.3390\/ijms25116207"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, et al. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024). Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu. 2024; 36: 240\u2013256.","DOI":"10.21147\/j.issn.1000-9604.2024.03.02"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021; 39: 3453\u20133462.","DOI":"10.1200\/JCO.21.00693"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Diamond A, Bensken WP, Vu L, Dong W, Koroukian SM, Caimi P. Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients. JACC. CardioOncology. 2023; 5: 233\u2013243.","DOI":"10.1016\/j.jaccao.2023.02.001"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023; 142: 687\u2013699.","DOI":"10.1182\/blood.2022018818"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2023; 388: 319\u2013332.","DOI":"10.1056\/NEJMoa2211582"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020; 136: 2038\u20132050.","DOI":"10.1182\/blood.2020006844"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018; 131: 2357\u20132366.","DOI":"10.1182\/blood-2017-12-820910"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sestier M, Hillis C, Fraser G, Leong D. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Current Oncology Reports. 2021; 23: 113.","DOI":"10.1007\/s11912-021-01102-1"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Trobec R, Jan M, Lind\u00e9n M, Toma\u0161i\u0107 I. Detection and Treatment of Atrial Irregular Rhythm with Body Gadgets and 35-channel ECG. In 2019 42nd International Convention on Information and Communication Technology, Electronics and Microelectronics (MIPRO). IEEE. 2019. https:\/\/","DOI":"10.23919\/MIPRO.2019.8756779"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. Journal of Hematology & Oncology. 2022; 15: 92.","DOI":"10.1186\/s13045-022-01302-7"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Johansson BB. Hypertension mechanisms causing stroke. Clinical and Experimental Pharmacology & Physiology. 1999; 26: 563\u2013565.","DOI":"10.1046\/j.1440-1681.1999.03081.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Proskuriakova E, Shrestha D, Jasaraj R, Mercado GE, Wortstman J, Kovalenko I, et al. CLL-428 Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia. 2023; 23: S327\u2013S328.","DOI":"10.1016\/S2152-2650(23)01112-6"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. Journal of Thrombosis and Haemostasis : JTH. 2017; 15: 835\u2013847.","DOI":"10.1111\/jth.13651"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Series J, Garcia C, Levade M, Viaud J, Si\u00e9 P, Ysebaert L, et al. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica. 2019; 104: 2292\u20132299.","DOI":"10.3324\/haematol.2018.207183"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Atallah-Yunes SA, Kadado AJ, Haddadin F, Sawalha K, Hernandez-Montfort J, Ali SS. Impact of cardiovascular comorbidities on inpatient mortality in patients hospitalized with neutropenic fever. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2021; 29: 509\u2013513.","DOI":"10.1007\/s00520-020-05518-6"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E, et al. The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation. Materia Socio-medica. 2017; 29: 231\u2013236.","DOI":"10.5455\/msm.2017.29.231-236"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thrombosis and Haemostasis. 2017; 117: 837\u2013850.","DOI":"10.1160\/TH16-11-0825"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Fernandez Turizo MJ, Kim E, Zhang C, Yankama T, Von Keudell G, Sermer DJ, et al. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. The Oncologist. 2025; 30: oyae229.","DOI":"10.1093\/oncolo\/oyae229"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Murru R, Innocenti I, Galitzia A, Tomasso A, Chessa C, Murineddu M, et al. Incidence of Atrial Fibrillation (AF) in Chronic Lymphocytic Leukemia (CLL) Patients: A Real-World Retrospective Comparison of Ibrutinib and Acalabrutinib. Blood. 2024; 144: 6779.","DOI":"10.1182\/blood-2024-208899"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2023; 41: 3988\u20133997.","DOI":"10.1200\/JCO.23.00562"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Review of Hematology. 2022; 15: 321\u2013331.","DOI":"10.1080\/17474086.2022.2067526"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Gambril JA, Ghazi S, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, et al. Arrhythmic Burden After Bruton's Tyrosine Kinase Inhibitor Initiation and Major Cardiovascular Events. Circulation. 2023; 148: A13214.","DOI":"10.1161\/circ.148.suppl_1.13214"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Poliner MC, Buck B, Ghazi S, Chen S, Gambril JA, Sansoterra S, et al. Abstract 17859: Real World Cardiovascular Events With Next Generation Bruton's Tyrosine Kinase Inhibitors - An Updated Analysis. Circulation. 2023; 148: A17859.","DOI":"10.1161\/circ.148.suppl_1.17859"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kiliszek M, Uzi\u0119b\u0142o-\u017byczkowska B, Gorczyca I, Maciorowska M, Jelonek O, Wo\u017cakowska-Kap\u0142on B, et al. Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine. 2021; 10: 1091.","DOI":"10.3390\/jcm10051091"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Lee EM. When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension. Clinical Hypertension. 2024; 30: 10.","DOI":"10.1186\/s40885-024-00265-w"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F, et al. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019; 140: 1792\u20131801.","DOI":"10.1161\/CIRCULATIONAHA.119.041346"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Carlisle MA, Shrader P, Fudim M, Pieper KS, Blanco RG, Fonarow GC, et al. Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation. Heart Rhythm O2. 2022; 3: 621\u2013628.","DOI":"10.1016\/j.hroo.2022.09.018"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Avalon JC, Fuqua J, Miller T, Deskins S, Wakefield C, King A, et al. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib. Cardio-oncology (London, England). 2021; 7: 38.","DOI":"10.1186\/s40959-021-00125-8"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England Journal of Medicine. 2014; 371: 213\u2013223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Advances. 2017; 1: 1739\u20131748.","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019; 133: 2031\u20132042.","DOI":"10.1182\/blood-2018-08-870238"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102: 1796\u20131805.","DOI":"10.3324\/haematol.2017.171041"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 2021; 21: S318.","DOI":"10.1016\/S2152-2650(21)01750-X"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, et al. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology. 2019; 37: 508\u2013512.","DOI":"10.1002\/hon.2655"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019; 134: 1919\u20131928.","DOI":"10.1182\/blood.2019000840"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PloS One. 2019; 14: e0211228.","DOI":"10.1371\/journal.pone.0211228"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125: 2497\u20132506.","DOI":"10.1182\/blood-2014-10-606038"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021; 39: 3441\u20133452.","DOI":"10.1200\/JCO.21.01210"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL. Blood. 2025; 146: 2168\u20132176.","DOI":"10.1182\/blood.2024028205"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. British Journal of Haematology. 2019; 184: 558\u2013569.","DOI":"10.1111\/bjh.15690"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 2015; 373: 2425\u20132437.","DOI":"10.1056\/NEJMoa1509388"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances. 2017; 1: 772\u2013778.","DOI":"10.1182\/bloodadvances.2016001883"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, et al. Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2023; 41: 1035\u20131045.","DOI":"10.1200\/JCO.22.00510"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126: 739\u2013745.","DOI":"10.1182\/blood-2015-03-635326"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Lu J, Do B, Primeaux B. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 2025; 31: 230\u2013235.","DOI":"10.1177\/10781552241232331"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 2016; 374: 323\u2013332.","DOI":"10.1056\/NEJMoa1509981"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology. 2019; 74: 1667\u20131678.","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Aguilar C. Ibrutinib-related bleeding: pathogenesis, clinical implications and management. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 2018; 29: 481\u2013487.","DOI":"10.1097\/MBC.0000000000000749"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Nunes RAB, Avezum \u00c1, de Oliveira Marques M, Baiocchi OC, Bachour P. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Annals of Hematology. 2024; 103: 4613\u20134620.","DOI":"10.1007\/s00277-024-05921-7"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ammad Ud Din M, Thakkar S, Patel H, Saeed H, Hussain SA, Liaqat H, et al. The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. Clinical Lymphoma, Myeloma & Leukemia. 2022; 22: 98\u2013104.","DOI":"10.1016\/j.clml.2021.08.006"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nature Reviews. Cancer. 2020; 20: 74\u201388.","DOI":"10.1038\/s41568-019-0216-7"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 612\u2013617.","DOI":"10.1073\/pnas.0606663104"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Qin H, Zheng B, Lin Z, Ji Y, Wang C, Zhu H, et al. Ibrutinib Contributes to Atrial Arrhythmia through the Autophagic Degradation of Connexins by Inhibiting the PI3K-AKT-mTOR Signaling Pathway. Frontiers in Bioscience (Landmark Edition). 2024; 29: 201.","DOI":"10.31083\/j.fbl2905201"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014; 124: 3829\u20133830.","DOI":"10.1182\/blood-2014-10-604272"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Denesiuk VI, Afanasiuk OI, Denesiuk OV, Muzyka NO. The Role of Vasodilation Factors in the Pathogenesis of Chronic Heart Failure of Ischemic Origin in Atrial Fibrillation. Science Review. 2021; 2: 528637.","DOI":"10.31435\/rsglobal_sr\/30042021\/7515"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Ko TH, Jeong D, Yu B, Song JE, Le QA, Woo SH, et al. Inhibition of late sodium current via PI3K\/Akt signaling prevents cellular remodeling in tachypacing-induced HL-1 atrial myocytes. Pflugers Archiv : European Journal of Physiology. 2023; 475: 217\u2013231.","DOI":"10.1007\/s00424-022-02754-z"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601\u2013605.","DOI":"10.1038\/21224"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Penna C, Pagliaro P. Endothelial Dysfunction: Redox Imbalance, NLRP3 Inflammasome, and Inflammatory Responses in Cardiovascular Diseases. Antioxidants (Basel, Switzerland). 2025; 14: 256.","DOI":"10.3390\/antiox14030256"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Xu J, Lin J, Gan H, He Q, Wang W, Liu Y. Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases. Frontiers in Pharmacology. 2025; 16: 1585061.","DOI":"10.3389\/fphar.2025.1585061"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Camp N, Garrett M, Gopal AK, James R. Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases. Blood. 2019; 134: 3795.","DOI":"10.1182\/blood-2019-124454"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Yang X, An N, Zhong C, Guan M, Jiang Y, Li X, et al. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation. Redox Biology. 2020; 30: 101432.","DOI":"10.1016\/j.redox.2020.101432"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. Journal of Hypertension. 2015; 33: 1128\u20131136.","DOI":"10.1097\/HJH.0000000000000587"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Huang PL. Endothelial nitric oxide synthase and endothelial dysfunction. Current Hypertension Reports. 2003; 5: 473\u2013480.","DOI":"10.1007\/s11906-003-0055-4"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Orzechowski HD. Endothelin-dependent modulation of vasoconstrictor action in the coronary circulation in early salt-induced experimental hypertension. Journal of Hypertension. 2003; 21: 27\u201329.","DOI":"10.1097\/00004872-200301000-00007"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Liu J, Liu Z, Zhang J, Chen X, Chen J, Sui L, et al. Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. Pharmaceutics. 2022; 14: 1876.","DOI":"10.3390\/pharmaceutics14091876"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Tsuchida R, Osawa T, Wang F, Nishii R, Das B, Tsuchida S, et al. BMP4\/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene. 2014; 33: 3803\u20133811.","DOI":"10.1038\/onc.2013.358"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Neubauer K, Zieger B. Endothelial cells and coagulation. Cell and Tissue Research. 2022; 387: 391\u2013398.","DOI":"10.1007\/s00441-021-03471-2"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Zhang D, Gong H, Meng F. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules (Basel, Switzerland). 2021; 26: 4907.","DOI":"10.3390\/molecules26164907"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Badran M, Gozal D. PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea? International Journal of Molecular Sciences. 2022; 23: 5516.","DOI":"10.3390\/ijms23105516"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacology & Therapeutics. 2018; 189: 89\u2013103.","DOI":"10.1016\/j.pharmthera.2018.04.009"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Kim J, Eckhart AD, Eguchi S, Koch WJ. Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. The Journal of Biological Chemistry. 2002; 277: 32116\u201332123.","DOI":"10.1074\/jbc.M204895200"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 2020; 142: 2443\u20132455.","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Torelli S, Jiang Y, Ayala A, Fazal M, Witteles RM, Baykaner T, et al. Abstract 18390: Ibrutinib Increases Ventricular Arrhythmia Burden Independently of Atrial Arrhythmia. Circulation. 2023; 148: A18390.","DOI":"10.1161\/circ.148.suppl_1.18390"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Mendez-Ruiz A, Lossos IS, Cohen MG. Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention. Journal of the Society for Cardiovascular Angiography & Interventions. 2023; 2: 100608.","DOI":"10.1016\/j.jscai.2023.100608"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124: 3991\u20133995.","DOI":"10.1182\/blood-2014-06-583294"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Nicolson PLR, Hughes CE, Watson S, Nock SH, Hardy AT, Watson CN, et al. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. Haematologica. 2018; 103: 2097\u20132108.","DOI":"10.3324\/haematol.2018.193391"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. The Journal of Pharmacology and Experimental Therapeutics. 2017; 363: 240\u2013252.","DOI":"10.1124\/jpet.117.242909"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Alu A, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022; 15: 138.","DOI":"10.1186\/s13045-022-01353-w"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn-Schmiedeberg's Archives of Pharmacology. 2006; 373: 245\u2013258.","DOI":"10.1007\/s00210-006-0080-3"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Dobie G, Kuriri FA, Omar MMA, Alanazi F, Gazwani AM, Tang CPS, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Advances. 2019; 3: 4298\u20134311.","DOI":"10.1182\/bloodadvances.2019000640"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT, Appleby N, Bruce D, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Advances. 2017; 1: 2610\u20132623.","DOI":"10.1182\/bloodadvances.2017011999"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Sim\u00f5es G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology. Microvascular Research. 2022; 143: 104398.","DOI":"10.1016\/j.mvr.2022.104398"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Hirooka Y. Sympathetic Activation in Hypertension: Importance of the Central Nervous System. American Journal of Hypertension. 2020; 33: 914\u2013926.","DOI":"10.1093\/ajh\/hpaa074"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Grassi G, Drager LF. Sympathetic overactivity, hypertension and cardiovascular disease: state of the art. Current Medical Research and Opinion. 2024; 40: 5\u201313.","DOI":"10.1080\/03007995.2024.2305248"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, et al. Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. The Oncologist. 2025; 30: oyaf237.","DOI":"10.1093\/oncolo\/oyaf237"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Xu ZQ, Li XZ, Zhu R, Ge R, Wei H, Shi HW, et al. Asprosin contributes to vascular remodeling in hypertensive rats via superoxide signaling. Journal of Hypertension. 2024; 42: 1427\u20131439.","DOI":"10.1097\/HJH.0000000000003751"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Yu M, Wu X, Peng L, Yang M, Zhou H, Xu J, et al. Inhibition of Bruton's Tyrosine Kinase Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Modulating Macrophage Polarization. Oxidative Medicine and Cellular Longevity. 2022; 2022: 6526036.","DOI":"10.1155\/2022\/6526036"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Wehrens XH, Van Oort RJ, Li N, Chelu M, Dobrev D. Abstract 2899: CaMKII Phosphorylation of RyR2 is Required for Atrial Fibrillation Induction in Mice. Circulation. 2009; 120: S713.","DOI":"10.1161\/circ.120.suppl_18.S713-a"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Munir T, \u010ciburien\u0117 E, Graklanov V, Gospodinova M, Jak\u0161i\u0107 O, Lipar L, et al. Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. Acta Haematologica. 2026; 149: 297\u2013312.","DOI":"10.1159\/000547426"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Gruessner C, Brofferio A, Tomasulo E, Superata J, Jose S, Soto S, et al. Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia. Blood. 2024; 144: 6787.","DOI":"10.1182\/blood-2024-205119"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC. CardioOncology. 2023; 5: 570\u2013590.","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022; 107: 1335\u20131346.","DOI":"10.3324\/haematol.2021.278901"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Qin Y, Zhao FY, Zhou Y, Jiang SY, Yang S, Shi YK. Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis. Zhonghua Zhong Liu Za Zhi. 2020; 42: 1034\u20131039.  (In Chinese)","DOI":"10.3760\/cma.j.cn112152-20200506-00410"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Advances. 2022; 6: 5516\u20135525.","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Zamorano JL, Lancellotti P, Mu\u00f1oz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiologia Polska. 2016; 74: 1193\u20131233.  (In Polish)","DOI":"10.5603\/KP.2016.0156"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Turizo MJF, Kim E, Asnani A, Yankama T, Von Keudell G, Mej\u00edas-De Jes\u00fas C. Pre-existing cardiovascular disease increases the risk of cardiovascular adverse events during Bruton tyrosine kinase inhibitor therapy. Blood. 2023; 142: 496.","DOI":"10.1182\/blood-2023-174560"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Jiang D, Song Z, Liu P, Wang Z, Zhao R. A prediction model for severe hematological toxicity of BTK inhibitors. Annals of Hematology. 2023; 102: 2765\u20132777.","DOI":"10.1007\/s00277-023-05371-7"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Sebastian IA, Gandhi DBC, Sylaja PN, Paudel R, Kalkonde YV, Yangchen Y, et al. Stroke systems of care in South-East Asia Region (SEAR): commonalities and diversities. The Lancet Regional Health. Southeast Asia. 2023; 17: 100289.","DOI":"10.1016\/j.lansea.2023.100289"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Proskuriakova E, Shrestha DB, Jasaraj R, Reddy VK, Shtembari J, Raut A, et al. Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis. Clinical Therapeutics. 2024; 46: 134\u2013145.","DOI":"10.1016\/j.clinthera.2023.11.014"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Godier A, Albaladejo P, French Working Group on Perioperative Haemostasis (GIHP). Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls. Journal of Clinical Medicine. 2020; 9: 2318.","DOI":"10.3390\/jcm9072318"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Wang K, Liu Q, Wu J, Cao Y, Wang S. The role of monitoring platelet function perioperatively and platelet transfusion for operated spontaneous intracerebral hemorrhage patients with long-term oral antiplatelet therapy: A case report. International Journal of Surgery Case Reports. 2021; 89: 106589.","DOI":"10.1016\/j.ijscr.2021.106589"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Shirley M. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features. Targeted Oncology. 2022; 17: 69\u201384.","DOI":"10.1007\/s11523-021-00857-8"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2019; 74: 104\u2013132.","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Leitinger DE, Kaplan DZ. BTK Inhibitors in Haematology: Beyond B Cell Malignancies. Transfusion Medicine Reviews. 2022; 36: 239\u2013245.","DOI":"10.1016\/j.tmrv.2022.06.009"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy. 2023; 8: 262.","DOI":"10.1038\/s41392-023-01469-6"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Turcs\u00e1nyi P, Kriegov\u00e1 E, Papaj\u00edk T. Cardiovascular side effects of signaling pathway inhibitors in chronic lymphocytic leukemia therapy. Onkologie. 2023; 17: 357\u2013362.  (In Czech)","DOI":"10.36290\/xon.2023.067"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Tavakoli GM, Yazdanpanah N, Rezaei N. Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments. Advances in Rheumatology (London, England). 2024; 64: 61.","DOI":"10.1186\/s42358-024-00401-y"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM47740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:07:43Z","timestamp":1783422463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/6\/10.31083\/RCM47740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02240-4"],"URL":"https:\/\/doi.org\/10.31083\/rcm47740","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"47740"}}